AbbVie recently experienced a 15% drop in stock price following the failure of its schizophrenia drug emraclidine in mid-stage trials, prompting analysts to reassess the company's future growth and pipeline.
The failure of emraclidine, which AbbVie acquired for $8.7 billion, represents a significant setback for the company as it faces declining sales from its once-dominant rheumatoid arthritis treatment Humira.
Despite AbbVie's positive earnings report and ongoing efforts like a new dividend increase, the failed drug trial highlights vulnerabilities in its strategy for future growth.
Collection
[
|
...
]